MRT 2359
Alternative Names: MRT-2359Latest Information Update: 22 Jun 2024
At a glance
- Originator Monte Rosa Therapeutics
- Class Antineoplastics; Carbamates; Ethers; Fluorobenzenes; Isoindoles; Ketones; Piperidines; Small molecules
- Mechanism of Action Peptide-chain-release factor 3 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Diffuse large B cell lymphoma; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Preclinical Prostate cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Prostate cancer in USA (PO)
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 08 Jan 2024 MRT 2359 receives Fast Track designation for Small cell lung cancer [PO] (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA